Progression of diabetic retinopathy in non treated fellow eye of patients treated with anti VEGF injections for diabetic macular oedema

Session Details

Session Title: Free Paper Session 7: Vascular Diseases & Diabetic Retinopathy II

Session Date/Time: Thursday 07/09/2017 | 14:30-16:00

Paper Time: 14:36

Venue: Room 117

First Author: : E.Tsianta UK

Co Author(s): :    D. Sim                             

Abstract Details


To determine progression of Diabetic Retinopathy in non treated eye in patients treated with intravitreal anti VEGF therapy for diabetic macular oedema (DMO).


Retrospective observational case series. Consecutive patients that received anti-VEGF therapy for DMO, treated with a series of anti-VEGF injections between August 2013 and Dec 2016 at a single site of Moorfields Eye Hospital, London.


Eighty three eyes of 83 consecutive patients with centre-involving DMO and central subfield macular thickness (CST) equal or greater than 350 mm on Topcon 3D OCT 2000, initiated on a loading phase of at least 3 intravitreal anti VEGF injections. The mean number of injections was 7.68 ( range 3-30). The mean follow up period was 11.73 months (SD±9.2). Subsequent retreatment was guided by VA and OCT with the aim of treating to stability. Resolution/no response and stability of macular oedema was recorded at the end of the treatment period. Progression of diabetic retinopathy was recorded at the initiation of treatment (baseline), 12 monthly and 24 monthly for both eyes .


The mean age of the patients was 69.1 (±11.1) years, and grading of Diabetic Retinopathy according to the United Kingdom Diabetic Retinopathy Screening (UKDRS) grades at baseline were R1:34 (41%), R2:21 (25%), R3S:22 (27%) and R3A:6 (7%) patients respectively in the untreated fellow eye . The mean number of injections was 7.68 (± 5,26). The response was recorded as complete recovery in 23 (28%), improvement: 46 (55%), no change: 13 (16%) and deterioration: 1 (1%) at the end of the follow up period. At 12 months, the grading of Diabetic Retinopathy was R1:34 (41%), R2:21 (25%), R3S:22 (27%) and R3A:6 (7%) in the treated eye and R1:35 (42%), R2:20 (24%), R3S:19 (23%) and R3A:9 (11%) in the non-treated eye respectively. At 24 months, the grading of Diabetic Retinopathy was R1:34 (41%), R2:21 (25%), R3S:26 (31%) and R3A:2 (2%) in the treated eye and R1:35 (42%), R2:19 (23%), R3S:18 (22%) and R3A:10 (12%) in the non-treated eye respectively.


Real world outcomes suggest improvement in diabetic retinopathy status in anti VEGF treated eye comparing to non-treated fellow eye of the patients who had unilateral treatment, manifested by an increase in the former and a decrease in the latter in ratio R3S/R3A respectively.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy